Table 1. Antimicrobial drugs using for MIC



Similar documents
日本化学療法学会雑誌第64巻第4号


日本化学療法学会雑誌第61巻第6号

Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis

CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote

VOL. 43 NO. 4


2 2 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 Feb Neisseria gonorrhoeae ceftriaxone CTRX % 2010 CTRX 20 FQ staphylococci, E. faecium, N.

VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus

CHEMOTHERAPY

THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium

Staphylococcus epidermidis Streptococcus pneumoniae Staphylococcus epidermidis Streptococcus pneumontae S. epidermidis Table 1. Summary of the organis

VOL.48 NO.7 lase negative staphylococci, Escherichia coli, Klebsiella spp., Citrobacter freundii, Enterobacter spp., indole-positive Proteus, Serratia

VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )


Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml

Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates

Fig.1 Chemical structure of BAY o 9867

coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F

Key words: change serotype, Pseudomonas aeruginosa anti-pseudomonal drug,

03-b-„FŒ{›xŒ¾-4.02

CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates

Key words:group D streptococci,classification,enterococcal infections, Antibiotic susceptibility,vancomycin

988 CHEMOTHERAPY NOV. 1971

49619, H. influenzae ATCC49247, C. jejuni ATCC 33252, C. fetus ATCC15296, B. fragilis ATCC 25285, C. soldellii ATCC9714, P. rnagnus ATCC lin (ABPC), e

THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 June 2015 Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis % 2 S. pneumon

Oct THE JAPANESE JOURNAL OF ANTIBIOTICS Pseudomonas aeruginosa 186 P. aeruginosa piperacillin PIPC, taz


Fig. 1 Chemical structure of DL-8280


Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile



CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study

(ABPC), Carbenicillin (CBPC), Surbenicillin (SBPC), Piperacillin (PIPC), Cephalexin (CEX), Cefaclor (CCL), Cephalothin (CET), Cefazolin (CEZ), Cefotia

epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia

CHEMOTHERAPY APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marc


THE JAPANESE JOURNAL OF ANTIBIOTICS ( 37 ) methicillin-susceptible Staphylococcus aureus (MSSA) Escherichia coli levof

1272 CHEMOTHERAPY MAR. 1975

THE JAPANESE JOURNAL OF ANTIBIOTICS ( 79)

日本化学療法学会雑誌第53巻第S-3号

R06_01

Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection


Dec THE JAPANESE JOURNAL OF ANTIBIOTICS ( 45 ) ) 1) 2) 2) 3) 4) 4,5) 6) 6) 7) 8) 8) 9) 10) 11) 11) 12) 13) 13) 14) 14) 15) 15) 1

Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood

CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin



Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent


PCG = Benzylpenicillin ABPC= Ampicillin AMPC= Amoxicillin MPIPC = Oxacillin MCIPC = Cloxacillin SBPC= Sulbenicillin PIPC= Piperacillin


日本化学療法学会雑誌第58巻第4号


pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P.


VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St

CHEMOTHERAPY


CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle

CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);


VOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin

CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz

02-(a)-Łi’ì™·Łv-4.11

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec LVFX 100 mg 3 / mg 2 / LVFX PK PD mg mg 1 1 AUC/MIC

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 Apr NTT NTT

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec DNA 2, , % 1.65% 1.17% 90% 9 Escherichia coli -


技術論文 Daptomycin の Etest 法による MIC 測定における 精度管理の重要性および問題点 中島 英恵 1) 1) 長野市民病院臨床検査科 長野県長野市富竹 要 旨 ダプトマイシン DAP 非感性株を含む Staphylococcus aureus

Table 1. MICs of fosfomycin and other antibiotics determined by agar dilution method against Pseudomonas aeruginosa FOM: fosfomycin, PIPC: piperacilli

特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書（案）

Feb THE JAPANESE JOURNAL OF ANTIBIOTICS Tebipenem pivoxil 1 1, Meiji Seika 2 Meiji Seika G 3 Meiji Seika Tebipen




CHEMOTHERAPY JUNE 1986

_02三浦.indd

CHEMOTHERAPY

Key words:fatty acid,plant oil,staphylococcus aureus,skin care, atopic dermatitis

VOL.42 S-1 methicillin-susceptible Staphylococcus aureus (MSSA), Staphylococcus epidermidis, Enterococcus faecalis, Escherichia coli, Klebsiella pneum


dihydrostreptomycin(sm), sulfanilamide(sa), kanamycin(km), paromomycin(prm), fradiomycin(frm), ampicillin(apc), cephaloridine (CER), nalidixic acid(na

VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega

Fig. 1 The sketch of the neonatal intensive care unit in Tokyo Women's Medical College Hospital. (1979)

DIC vegetation 1 nonbacterial thrombogenic e


Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone


Key Words: Klebsiella pneumoniae, CEP-AIS, MIC, "MBC", MIC of drugs in combination


CHEMO THE RAPY OCT. 1994

(2003)

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 3 June 2012 NTT



Key words: Streptococcus pyogenes, Streptococcus dysgalactiae subsp. equisimilis, rapid diagnosis

R01

Transcription:

Table 1. Antimicrobial drugs using for MIC

Table 2. Susceptibilities determined with the VITEK 2 system and agar dilution reference by interpretive eategory for Staphylococcus aureus Table 3. Interpretive discrepancies by the VITEK 2 system and agar dilution reference for Staphylococcus aureus isolates N. A.: not applicable

Table 4. Susceptibilities determined with the VITEK 2 system and agar dilution reference by interpretive category for Streptocoeeus pneumoniae Table 5. Interpretive discrepancies by the VITEK 2 system and agar dilution reference for Streptococcus pneumoniae isolates N. A.: not applicable Table 6. Susceptibilities determined with the VITEK 2 system and agar dilution reference by interpretive category for Enterococcus

Table 7. Interpretive discrepancies by the VITEK 2 system and agar dilution reference for Enterococcus isolates N. A.: not applicable

Table 8. Susceptibilities determined with the VITEK 2 system and agar dilution reference by interpretive category for Pseudomonas aerugmosa CAZ: ceftazidime, IPM: imipenem Table 9. Interpretive discrepancies by the VITEK 2 system and agar dilution reference for Pseudomonas aeruginosa isolates N. A.: not applicable CAZ: ceftazidime, IPM: imipenem

1) National Committee for Clinical Laboratory Standards: Performance Standards for Antimicrobial Susceptibility Testing; Ninth informational Supplement. M 100-S 9, 1999 Financial benefits of rapid bacterial identification and antimicrobial susceptibility testing. J Clin 3) Barenfanger J, Drake C, Kacich G: Clinical and Microbiol 37: 1415 `1418, 1999 4) Doern G V, Brueggemann A B, Perla R, et al.: Multicenter laboratory of evaluation of the biomerieux VITEK antimicrobial susceptibility testing system with 11 antimicrobial agents versus members of the family Enterobacteriaceae and Pseudomonas aeruginosa. J Clin Microbiol 35: 2115 2119, 1997 Chemother 34: 1238 `1244, 1986 9) Knapp C C, Ludwig M D, Washington J A,: Evaluation of differential inoculum disk diffusion method and VITEK GPS-SA card for detection of oxacillinresistant Staphylococci. J Clin Microbiol 32: 433 ` 436, 1994 10) Garcia-garrote F, Cercenado E, Bouza E: Evaluation of a new system, VITEK 2, for identification and antimicrobial susceptibility testing of Enterococci. J Clin Microbiol 38: 2108 `2111, 2000 12) Biedenbach D J, Jones R N: Interpretive errors using an automated system for the susceptibility ` testing of imipenem and aztreonam. Diagn Microbiol Infect Dis 21: 57 `60, 1995

Evaluation of a new VITEK 2 system for antimicrobial-susceptibility testing of 434 clinical isolates Hiroe Muraoke, Takako Nishiyama1), Hideaki Koyama1), Miyuki Hasegawa1), Intetsu Kobayashi1,2) and Keizou Yamaguchi2)1 )Ch emotherapy Div., Mitsubishi Kagaku BCL, 3-30-1 Shimura, Itabashi-ku, Tokyo 174-8555, Japan Dept. of Microbiol., Toho Univ. Sch. of Med. Our study was to evaluate a VITEK 2 system to determine antimicrobial susceptibility in clinical isolates. The 434 strains tested consisted of 111 Staphylococcus aureus (MRSA, MSSA), 108 Enterococcus, 113 Streptococcus pneumoniae (PSSP, PISP, PRSP), and 102 Pseudomonas aeruginosa. Antimicrobial susceptibility tests were evaluated by comparing the VITEK 2 system to S, I, and R categories - determined by agar dilution following the standard method of the Japan Society of Chemotherapy. Similar results were obtained for MRSA by both methods wherein approximately 40% of tested strains were resistant to gentamicin (GM) and 70% to ofloxacin (OFLX), while all were susceptible to vancomycin (VCM) and sulfamethoxazole-trimethoprim (ST). With PISP, PRSP agar dilution, approximately 20% of ceftriaxone (CTRX) and cefotaxime (CTX) and 66% of imipenem (IPM) were determined to be "I", The susceptibility result for CTRX obtained by the VITEK 2 system agreed well with that obtained by agar dilution. The VITEK 2 system determined 64% as "I" for CTX and all strains as "S" for IPM, showing a tendency for CTX to be resistant and IPM to be susceptible compared to agar dilution. For Enterococcus, many penicillin G (PCG)-resistant strains were seen in Enterococcus faecium. Enterococcus faecalis and Enterococcus faecium determined as VCM-resistant by agar dilution showed the same results as for the VITEK 2 system. For ceftazidime (CAZ)-resistant P. aeruginosa, many strains were resistant to Ĉ-lactams, including piperacillin (PIPC) and cefpirome, but were susceptible to quinolones such as ciprofloxacin and levofloxacin. Approximately 70% of IPM-resistant strains were susceptible to PIPC and CAZ, and about half were resistant to quinolones. Results obtained by agar dilution and the VITEK 2 system thus agreed closely. In conclusion, these results demonstrate that VITEK 2 system performance is equivalent to agar dilution MIC reference and useful in routine clinical microbiology laboratory procedures.

2024 © docsplayer.net プライバシー | 利用規約 | フィードバック